 | • レポートコード：MRC2303J0228 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、233ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートによると、2021年に303.4億ドルであった世界の院内感染対策市場規模は、2022年に320.9億ドルになり、2027年までにCAGR 5.93％で拡大して428.9億ドルに達するとみられています。本書は、院内感染対策の世界市場を対象とした調査結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（消耗品、消毒剤、内視鏡リプロセッサー、感染防止＆監視ソフトウェア、微生物検査機器）分析、病原体類別（細菌、真菌、ウイルス）分析、疾患別（血流感染症、胃腸感染症、院内肺炎、手術部位感染症、尿路感染症）分析、エンドユーザー別（外来手術＆診断センター、病院＆ICU、介護施設＆産院）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、下記の項目を掲載しています。なお、本書内の企業情報としては、3M Company、Abbott Laboratories、Advanced Sterilization Products Services Inc.、Becton, Dickinson and Company、Belimed AG、BioMerieux SA、Cantel Medical Corporation、F. Hoffmann-La Roche Ltd、Kimberly-Clark Corporationなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の院内感染対策市場規模：種類別 - 消耗品の市場規模 - 消毒剤の市場規模 - 内視鏡リプロセッサーの市場規模 - 感染防止＆監視ソフトウェアの市場規模 - 微生物検査機器の市場規模 ・世界の院内感染対策市場規模：病原体類別 - 細菌性感染症における市場規模 - 真菌性感染症における市場規模 - ウイルス性感染症における市場規模 ・世界の院内感染対策市場規模：疾患別 - 血流感染症における市場規模 - 胃腸感染症における市場規模 - 院内肺炎における市場規模 - 手術部位感染症における市場規模 - 尿路感染症における市場規模 ・世界の院内感染対策市場規模：エンドユーザー別 - 外来手術＆診断センターにおける市場規模 - 病院＆ICUにおける市場規模 - 介護施設＆産院における市場規模 ・世界の院内感染対策市場規模：地域別 - 南北アメリカの院内感染対策市場規模 アメリカの院内感染対策市場規模 カナダの院内感染対策市場規模 ブラジルの院内感染対策市場規模 ... - アジア太平洋の院内感染対策市場規模 日本の院内感染対策市場規模 中国の院内感染対策市場規模 インドの院内感染対策市場規模 韓国の院内感染対策市場規模 台湾の院内感染対策市場規模 ... - ヨーロッパ/中東/アフリカの院内感染対策市場規模 イギリスの院内感染対策市場規模 ドイツの院内感染対策市場規模 フランスの院内感染対策市場規模 ロシアの院内感染対策市場規模 ... - その他地域の院内感染対策市場規模 ・競争状況 ・企業情報 |
The Global Hospital Acquired Infection Control Market size was estimated at USD 30.34 billion in 2021 and expected to reach USD 32.09 billion in 2022, and is projected to grow at a CAGR 5.93% to reach USD 42.89 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Hospital Acquired Infection Control to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Consumables, Disinfectants, Disinfectors, Endoscope Reprocessors, Infection Prevention & Surveillance Software, Microbial Testing Instruments, Others, Reagents, and Sterilizers.
Based on Pathogen Type, the market was studied across Bacterial, Fungal, and Viral.
Based on Indication, the market was studied across Bloodstream Infections, Gastrointestinal Infections, Hospital Acquired Pneumonia, Surgical Site Infections, and Urinary Tract Infections.
Based on End User, the market was studied across Ambulatory Surgical & Diagnostic Centers, Hospitals & ICUs, and Nursing Homes & Maternity Centers.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Hospital Acquired Infection Control market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Hospital Acquired Infection Control Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Hospital Acquired Infection Control Market, including 3M Company, Abbott Laboratories, Advanced Sterilization Products Services Inc., Becton, Dickinson and Company, Belimed AG, BioMerieux SA, Cantel Medical Corporation, F. Hoffmann-La Roche Ltd, Kimberly-Clark Corporation, Merck & Co., Inc., Olympus Corporation, Pfizer Inc., Sterigenics International LLC., Steris Corporation, and Synergy Health, PLC.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Hospital Acquired Infection Control Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Hospital Acquired Infection Control Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hospital Acquired Infection Control Market?
4. What is the competitive strategic window for opportunities in the Global Hospital Acquired Infection Control Market?
5. What are the technology trends and regulatory frameworks in the Global Hospital Acquired Infection Control Market?
6. What is the market share of the leading vendors in the Global Hospital Acquired Infection Control Market?
7. What modes and strategic moves are considered suitable for entering the Global Hospital Acquired Infection Control Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing geriatric population with the increase in the number of chronic diseases
5.1.1.2. Rapidly growing emphasis on infection control policies
5.1.1.3. Increasing use of disinfectors and medical nonwovens in the healthcare industry
5.1.2. Restraints
5.1.2.1. Lack of awareness regarding hospital acquired infection
5.1.3. Opportunities
5.1.3.1. Increasing investments in R&D coupled with high usage of consumables in hospitals
5.1.3.2. Innovative technologies implemented in devices that control infection
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements
5.2. Cumulative Impact of COVID-19
6. Hospital Acquired Infection Control Market, by Type
6.1. Introduction
6.2. Consumables
6.3. Disinfectants
6.4. Disinfectors
6.5. Endoscope Reprocessors
6.6. Infection Prevention & Surveillance Software
6.7. Microbial Testing Instruments
6.8. Others
6.9. Reagents
6.10. Sterilizers
7. Hospital Acquired Infection Control Market, by Pathogen Type
7.1. Introduction
7.2. Bacterial
7.3. Fungal
7.4. Viral
8. Hospital Acquired Infection Control Market, by Indication
8.1. Introduction
8.2. Bloodstream Infections
8.3. Gastrointestinal Infections
8.4. Hospital Acquired Pneumonia
8.5. Surgical Site Infections
8.6. Urinary Tract Infections
9. Hospital Acquired Infection Control Market, by End User
9.1. Introduction
9.2. Ambulatory Surgical & Diagnostic Centers
9.3. Hospitals & ICUs
9.4. Nursing Homes & Maternity Centers
10. Americas Hospital Acquired Infection Control Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Hospital Acquired Infection Control Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Hospital Acquired Infection Control Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. 3M Company
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Abbott Laboratories
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Advanced Sterilization Products Services Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Becton, Dickinson and Company
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Belimed AG
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. BioMerieux SA
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Cantel Medical Corporation
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. F. Hoffmann-La Roche Ltd
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Kimberly-Clark Corporation
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Merck & Co., Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Olympus Corporation
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Pfizer Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Sterigenics International LLC.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Steris Corporation
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Synergy Health, PLC
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing